标题
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
作者
关键词
-
出版物
CURRENT OPINION IN LIPIDOLOGY
Volume 34, Issue 6, Pages 243-251
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2023-08-23
DOI
10.1097/mol.0000000000000897
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
- (2023) Hye Duck Choi et al. Cardiovascular Therapeutics
- Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
- (2023) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome
- (2023) P. Gabriel Steg et al. CANADIAN JOURNAL OF CARDIOLOGY
- Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
- (2023) Leopoldo Pérez de Isla et al. CIRCULATION
- Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE
- (2023) Prakriti Gaba et al. CIRCULATION
- Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent
- (2023) Salvatore Giordano et al. CURRENT OPINION IN LIPIDOLOGY
- Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
- (2023) Christie M. Ballantyne et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
- (2023) Steven E. Nissen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES
- (2022) Chern-En Chiang et al. CANADIAN JOURNAL OF CARDIOLOGY
- Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
- (2022) Remo H.M. Furtado et al. Circulation-Cardiovascular Interventions
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
- (2022) Lorenz Räber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
- (2022) Laura E. Korthauer et al. PLoS One
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
- (2022) Stephen J. Nicholls et al. JACC-Cardiovascular Imaging
- Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2022) Petr Ostadal et al. Lancet Diabetes & Endocrinology
- Lipoprotein(a) and its Significance in Cardiovascular Disease
- (2022) Freddy Duarte Lau et al. JAMA Cardiology
- Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis
- (2022) Yue Zhang et al. Cardiology Research and Practice
- Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
- (2022) Gregory G. Schwartz et al. CURRENT OPINION IN LIPIDOLOGY
- Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
- (2022) Yan Hao et al. International Heart Journal
- Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia
- (2022) Daniel Gaudet et al. Journal of Clinical Lipidology
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
- (2022) Michelle L. O’Donoghue et al. CIRCULATION
- Efficacy and Safety of an Investigational Single-course CRISPR Base Editing Therapy Targeting PCSK9 in Non-human Primate and Mouse Models
- (2022) Richard G. Lee et al. CIRCULATION
- Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
- (2022) Emil Hagström et al. CIRCULATION
- Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice
- (2022) Amir Abbas Momtazi-Borojeni et al. BIOMEDICINE & PHARMACOTHERAPY
- Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study
- (2021) Hideaki Ota et al. European Heart Journal-Cardiovascular Imaging
- Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study
- (2021) Matthew J. Janik et al. ATHEROSCLEROSIS
- Cholesterol: the race to the bottom
- (2021) Eugene Braunwald EUROPEAN HEART JOURNAL
- Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial
- (2021) Kazuma Oyama et al. EUROPEAN HEART JOURNAL
- Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography
- (2021) Fei Gao et al. Lipids in Health and Disease
- Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
- (2021) Bhavani Shankara Bagepally et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
- (2020) Baris Gencer et al. JAMA Cardiology
- Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period
- (2020) Thorsten M. Leucker et al. CIRCULATION
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome ― The ODYSSEY J-IVUS Trial ―
- (2019) Junya Ako et al. CIRCULATION JOURNAL
- Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome
- (2019) Hideki Yano et al. Journal of Cardiology
- Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS)
- (2019) Konstantinos C. Koskinas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipid management in ACS: Should we go lower faster?
- (2018) Gencer Baris et al. ATHEROSCLEROSIS
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
- (2018) Michel Farnier et al. ATHEROSCLEROSIS
- Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin
- (2018) Hiromasa Otake et al. Journal of Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
- (2017) Nihar R. Desai et al. JAMA Cardiology
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started